Kura Oncology (KURA) Interest Expenses (2010 - 2026)

Kura Oncology (KURA) has 17 years of Interest Expenses data on file, last reported at $7.9 million in Q1 2026.

• On a quarterly basis, Interest Expenses rose 1875.0% year-over-year to $7.9 million in Q1 2026; TTM through Mar 2026 was $7.9 million, a 384.37% increase from a year earlier, with the FY2025 full-year figure at $363.9 million, up 30.49% from the prior year.
• Interest Expenses for Q1 2026 stood at $7.9 million, up from $346000.0 in the prior quarter.
• Over the last five years, Interest Expenses for KURA reached as high as $25.1 million in Q2 2025 and fell as low as -$151000.0 in Q4 2023.
• Historically, Interest Expenses has averaged $3.3 million across 5 years, with a median of $600000.0 in 2022.
• Across the five-year window, Interest Expenses sank 125.17% in 2023 and jumped 4913.6% in 2025, its largest moves.
• Year by year, Interest Expenses stood at $600000.0 in 2022, then plunged by 125.17% to -$151000.0 in 2023, then soared by 311.26% to $319000.0 in 2024, then advanced by 8.46% to $346000.0 in 2025, then surged by 2183.24% to $7.9 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $7.9 million in Q1 2026, $346000.0 in Q4 2025, and $500000.0 in Q3 2025.